Abstract
AbstractEmerging heart-on-a-chip platforms are promising approaches to establish cardiac cell/tissue models in vitro for research on cardiac physiology, disease modeling and drug cardiotoxicity as well as for therapeutic discovery. Challenges still exist in obtaining the complete capability of in situ sensing to fully evaluate the complex functional properties of cardiac cell/tissue models. Changes to contractile strength (contractility) and beating regularity (rhythm) are particularly important to generate accurate, predictive models. Developing new platforms and technologies to assess the contractile functions of in vitro cardiac models is essential to provide information on cell/tissue physiologies, drug-induced inotropic responses, and the mechanisms of cardiac diseases. In this review, we discuss recent advances in biosensing platforms for the measurement of contractile functions of in vitro cardiac models, including single cardiomyocytes, 2D monolayers of cardiomyocytes, and 3D cardiac tissues. The characteristics and performance of current platforms are reviewed in terms of sensing principles, measured parameters, performance, cell sources, cell/tissue model configurations, advantages, and limitations. In addition, we highlight applications of these platforms and relevant discoveries in fundamental investigations, drug testing, and disease modeling. Furthermore, challenges and future outlooks of heart-on-a-chip platforms for in vitro measurement of cardiac functional properties are discussed.
Funder
Gouvernement du Canada | Canadian Institutes of Health Research
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada
Publisher
Springer Science and Business Media LLC
Subject
Electrical and Electronic Engineering,Industrial and Manufacturing Engineering,Condensed Matter Physics,Materials Science (miscellaneous),Atomic and Molecular Physics, and Optics
Reference225 articles.
1. Benjamin, E. J. Heart disease and stroke Statistics-2019 update a report from the American Heart Association. Circulation. 139, e56–e528 (2019).
2. Samson, R., Ramachandran, R. & Le Jemtel, T. H. Systolic heart failure: knowledge gaps, misconceptions, and future directions. Ochsner J. 14, 569–575 (2014).
3. Berry, C., Murdoch, D. R. & McMurray, J. J. V. Economics of chronic heart failure. Eur. J. Heart Fail 3, 283–291 (2001).
4. Ye, L., Ni, X., Zhao, Z. A., Lei, W. & Hu, S. The application of induced pluripotent stem cells in cardiac disease modeling and drug testing. J. Cardiovasc. Transl. Res. 11, 366–374 (2018).
5. Mudd, J. O. & Kass, D. A. Tackling heart failure in the twenty-first century. Nature 451, 919–928 (2008).
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献